Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lance Shinn

Internal Medicine Daniels, WV Doctor of Osteopathy

NPI 1316468192 CMS profile 4000907

2157 Ritter Dr, Daniels, WV 25832

Open in the dashboard

General payments

$2,730

151 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lance Shinn of Daniels, WV is reported in the CMS Open Payments database as having received $2,730 across 151 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $329 20
2024 General $588 33
2023 General $734 40
2022 General $912 51
2021 General $94 6
2019 General $74 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lance Shinn
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Lance Shinn were reported at $329. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Lance Shinn Internal Medicine median Middle half National median
2019 $74 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $94 $135 $37–$521 $132
2022 $912 $141 $42–$496 $149
2023 $734 $149 $45–$519 $160
2024 $588 $154 $47–$537 $164
2025 $329 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $931 60 payments
  2. Medtronic, Inc. $323 11 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $293 19 payments
  4. AbbVie, Inc. $265 19 payments
  5. Averitas Pharma Inc. $208 10 payments
  6. Curonix LLC $191 5 payments
  7. Janssen Pharmaceuticals, Inc $74 1 payment
  8. Relievant Medsystems, Inc. $55 3 payments
  9. Pfizer Inc. $51 3 payments
  10. Abbott Laboratories $42 2 payments
  11. Other $298 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,730 151 payments
Products named General payments · program years 2019–2025
  1. Ozempic $503 35 payments
  2. RYBELSUS $421 30 payments
  3. XIFAXAN $293 19 payments
  4. Qutenza $208 10 payments
  5. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $191 5 payments
  6. Micra $175 1 payment
  7. QULIPTA $133 8 payments
  8. VRAYLAR $108 10 payments
  9. XARELTO $74 1 payment
  10. VANTA ADAPTIVESTIM $69 4 payments
  11. Other $912 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 128 drugs

Part D claims

6,539

Median for General Practice: 1,105

Drug cost

$586,735

Median for General Practice: $48,734

Branded share of claims

21.8%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 95 $183,427
Eliquis Apixaban Brand 69 $82,954
Mounjaro Tirzepatide Brand 37 $46,148
Januvia Sitagliptin Phosphate Brand 20 $34,033
Rybelsus Semaglutide Brand 12 $28,956
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 43 $28,340
Jardiance Empagliflozin Brand 21 $22,923
Farxiga Dapagliflozin Propanediol Brand 25 $19,457
Wegovy Semaglutide Brand 13 $19,297
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 16 $14,456

The 10 drugs with the highest cost, of 128 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $144
$144 — —
Qutenza
  • Averitas Pharma Inc. $64
$64 — —
RYBELSUS
  • Novo Nordisk Inc $40
$40 12 —
Ozempic
  • Novo Nordisk Inc $40
$40 95 —
UBRELVY
  • AbbVie, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

151 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record